ATE423778T1 - Verfahren zur herstellung von anthranilsäurederivat-hydrat - Google Patents

Verfahren zur herstellung von anthranilsäurederivat-hydrat

Info

Publication number
ATE423778T1
ATE423778T1 AT03727661T AT03727661T ATE423778T1 AT E423778 T1 ATE423778 T1 AT E423778T1 AT 03727661 T AT03727661 T AT 03727661T AT 03727661 T AT03727661 T AT 03727661T AT E423778 T1 ATE423778 T1 AT E423778T1
Authority
AT
Austria
Prior art keywords
hydrate
acid derivative
anthranilic acid
filtrate
pharmaceutically acceptable
Prior art date
Application number
AT03727661T
Other languages
English (en)
Inventor
David HAYMAN
Michael Wright
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Application granted granted Critical
Publication of ATE423778T1 publication Critical patent/ATE423778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03727661T 2002-05-14 2003-05-13 Verfahren zur herstellung von anthranilsäurederivat-hydrat ATE423778T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37975902P 2002-05-14 2002-05-14

Publications (1)

Publication Number Publication Date
ATE423778T1 true ATE423778T1 (de) 2009-03-15

Family

ID=29420557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03727661T ATE423778T1 (de) 2002-05-14 2003-05-13 Verfahren zur herstellung von anthranilsäurederivat-hydrat

Country Status (11)

Country Link
US (1) US7524861B2 (de)
EP (1) EP1506188B1 (de)
JP (1) JP4464814B2 (de)
KR (1) KR101060971B1 (de)
CN (1) CN100349888C (de)
AT (1) ATE423778T1 (de)
AU (1) AU2003233899B2 (de)
BR (1) BR0309990A (de)
CA (1) CA2485430C (de)
DE (1) DE60326341D1 (de)
WO (1) WO2003095447A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
WO2007075901A2 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2819670B1 (de) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmazeutische zubereitung und deren verabreichungen
PL3027171T3 (pl) 2013-07-30 2020-08-24 Gilead Connecticut, Inc. Formulacja inhibitorów syk
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
CN104434947B (zh) * 2014-11-07 2016-11-09 滨州医学院附属医院 一种抗胆管癌的药物组合物及其应用
EP3378858A1 (de) * 2017-03-21 2018-09-26 Bioprojet Tetrahydrat von h3-ligand, verfahren zu dessen herstellung und pharmazeutische zusammensetzungen damit
KR20220070056A (ko) 2017-08-25 2022-05-27 길리애드 사이언시즈, 인코포레이티드 Syk 억제제의 다형체
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
AU2021358977A1 (en) * 2020-10-07 2023-04-27 Health Hope Pharma Hk Limited Acetamido-phenylbenzamide derivatives and methods of using the same
CN112724124A (zh) * 2021-01-18 2021-04-30 林剑雄 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK280864B6 (en) * 1991-01-11 2000-08-14 Laboratoires Glaxo Sa Acridine derivatives, process for their preparation, and pharmaceutical compositions based thereon
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
HUP0001531A3 (en) * 1996-10-18 2000-09-28 Xenova Ltd Slough Anthranilic acid derivatives as multi drug resistance modulators

Also Published As

Publication number Publication date
CN1665806A (zh) 2005-09-07
EP1506188B1 (de) 2009-02-25
WO2003095447A1 (en) 2003-11-20
JP2005538051A (ja) 2005-12-15
KR101060971B1 (ko) 2011-09-01
CN100349888C (zh) 2007-11-21
US20050222199A1 (en) 2005-10-06
EP1506188A1 (de) 2005-02-16
AU2003233899B2 (en) 2009-03-12
JP4464814B2 (ja) 2010-05-19
KR20050009706A (ko) 2005-01-25
DE60326341D1 (de) 2009-04-09
BR0309990A (pt) 2005-02-22
CA2485430C (en) 2011-12-06
CA2485430A1 (en) 2003-11-20
US7524861B2 (en) 2009-04-28
AU2003233899A1 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
DE60326341D1 (de) Verfahren zur herstellung von anthranilsäurederivat-hydrat
CN104936961B (zh) (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
NO20052912L (no) Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil
US11897843B2 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
ATE366725T1 (de) Verfahren zur herstellung von gereinigten 1,3- substituierten imidazoliumsalzen
CA2968436A1 (en) Method for the production of praziquantel and precursors thereof
JP2002514648A (ja) (s,s)−ベンジル−2,8−ジアザビシクロ[4.3.0]ノナンの製造方法
ATE299144T1 (de) Verfahren zur herstellung einer pharmazeutisch aktiven verbindung (granisetron)
JP2010510253A5 (de)
ATE515496T1 (de) Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure
RU2006102357A (ru) Способ управления кристаллической структурой ризедроната
RU2387656C2 (ru) Способ получения гидробромида галантамина
BR112020010618B1 (pt) Método para preparar acetato de salicilamina
ATE297933T1 (de) Ein verfahren zur herstellung von hochreinem cefpodoxim-proxetil
ATE316082T1 (de) Prozess zur herstellung von r(+)alpha-liponsäure
ATE325797T1 (de) Verfahren zur herstellung von hochreinem triethylendiamin
DE50307171D1 (de) Verfahren zur herstellung von 3-amidinophenylalanin-derivaten
ATE403658T1 (de) Verfahren zur herstellung einer lösung von reinem triethylendiamin (teda)
ATE402157T1 (de) Verfahren zur herstellung von mycophenolatmofetil
ATE370950T1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol
ATE472523T1 (de) Verbessertes verfahren zur herstellung von rivastigmin
JPH1036327A (ja) 1−(3−メトキシフェニル)エチルアミンの光学活性体の製造方法
ATE375355T1 (de) Verfahren zur herstellung von cefpodoxim-proxetil
RU2741389C1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
JP2009062392A (ja) 環化法

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties